"Kailash Cancer Hospital & Research Centre has provided the finest medical Care service to the people of Southeastern Gujarat. It is ranked as one of India's Leading Cancer Hospitals, based on the number of patients diagnosed and treated annually. The hospital is designed to provide curative and preventive treatment, post therapy support service, palliative care in hospice and domiciliary facility. Apart from Cancer treatment, it is the only facility in India to have a dedicated range of pediatric services. It is also know as best in class for: Gynecology & Obstetric General Surgery Critical Care Services Diabetes Treatment Urology Full time - Diagnostic Imaging / Radiology / 16 Slice C.T. Scan / X Ray departments"

During the past decade, Kailash Cancer Hospital And Research Center conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 2 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kailash Cancer Hospital And Research Center" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Aurigene Discovery Technologies Limited" with 1 trials sponsored, "Ayana Pharma Ltd.," with 1 trials sponsored, "CanariaBio Inc." with 1 trials sponsored and "Gemin X" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kailash Cancer Hospital And Research Center" #1 collaborator was "Actoverco" with 1 trials as a collaborator, "Cephalon" with 1 trials as a collaborator, "Innogene Kalbiotech Pte. Ltd" with 1 trials as a collaborator, "Key Oncologics (Pty) Ltd" with 1 trials as a collaborator and "Laboratorio Elea Phoenix S.A." with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Kailash Cancer Hospital And Research Center" are "Buccal Mucosa Cancer" (1 trials), "Cancer of Mouth" (1 trials), "Cancer of the Head and Neck" (1 trials), "Cancer of the Tongue" (1 trials) and "Diffuse Large B-cell Lymphoma" (1 trials). Many other conditions were trialed in "Kailash Cancer Hospital And Research Center" in a lesser frequency.

Most popular intervention types in "Kailash Cancer Hospital And Research Center" are "Drug" (6 trials), "Biological" (3 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "AUR105" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials), "Bevacizumab as Avastin" (1 trials), "Bevacizumab as MYL-1402O" (1 trials) and "Carboplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kailash Cancer Hospital And Research Center" are 7 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Kailash Cancer Hospital And Research Center". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Kailash Cancer Hospital And Research Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Kailash Cancer Hospital And Research Center, 3 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".